Rare Cancer Drug Cuts Death Risk by 45% in Trial

Patients fighting one of the rarest and most aggressive cancers just got their first real weapon in a battle that has had few options until now.

A new drug called abemaciclib has shown remarkable results against advanced dedifferentiated liposarcoma, a soft-tissue cancer that typically returns after surgery with devastating speed. In a Phase III clinical trial, the medication reduced deaths by 45% and gave patients an additional 8.2 months without their disease progressing.

The numbers tell a powerful story. Patients taking abemaciclib lived a median of 9.7 months without their cancer worsening, compared to just 1.5 months for those on placebo. That represents a 62% reduction in the risk of disease progression or death.

Dr. Mark Dickson of Memorial Sloan Kettering Cancer Center presented the findings at the 2026 ASCO Annual Meeting. He explained that scientists chose this particular drug because nearly all cases of this cancer share a specific genetic quirk: amplification of a gene called CDK4 that drives tumor growth.

Researchers have been pursuing this approach since 2010, when early studies showed CDK4 inhibitors could stop liposarcoma cells from growing in laboratory experiments. Years of research led them to abemaciclib, which proved more effective and caused fewer side effects than similar drugs because it targets CDK4 more precisely.

The trial was conducted by the Sarcoma Alliance for Research through Collaboration, a group dedicated to finding treatments for ultra-rare tumors. They compared abemaciclib against placebo rather than chemotherapy because standard chemo treatments for this cancer cause serious side effects without offering much benefit.

At six months, 60% of patients taking the new drug remained progression-free, compared to just 22% on placebo. By twelve months, those numbers were 39% and 13% respectively.

The Bright Side

This breakthrough matters beyond the numbers. Dedifferentiated liposarcoma has long been an orphan disease, meaning it affected too few people for pharmaceutical companies to invest in treatments. Patients faced a grim reality: surgery, hope it doesn't come back, and limited options when it inevitably did.

Now, for the first time, doctors can offer a targeted therapy backed by rigorous science. The treatment works with the disease's own biology against it, blocking the exact mechanism that fuels tumor growth.

For rare disease communities everywhere, this trial demonstrates that even the smallest patient populations deserve cutting-edge research and that persistence in pursuing targeted therapies can pay off after years of work.

Patients with this rare cancer finally have reason for hope.